Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Tyrosine kinase-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Syk (1) Apoptosis (1) Autophagy (1) Bcr-Abl (2) c-Fms (3) c-Kit (3) c-Met/HGFR (4) Drug Metabolite (1) EGFR (1) FGFR (1) HIF/HIF Prolyl-Hydroxylase (1) IGF-1R (1) Insulin Receptor (3) Isotope-Labeled Compounds (1) PDGFR (3) ROS Kinase (1) Src (1) TAM Receptor (1) VEGFR (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (1) Metabolic Disease (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Btk Syk DYRK Pyk2 AIM2 NEKs BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100315

**Tyrosine kinase-IN-1**	VEGFR PDGFR FGFR	Cardiovascular Disease
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.

HY-132844

Tunlametinib

HL-085
c-Met/HGFR Cancer

Tunlametinib, an antineoplastic agent, is a tyrosine kinase inhibitor .
HY-156619

Labuxtinib

c-Kit Cancer

Labuxtinib is c-kit tyrosine kinase inhibitor .
HY-147612

Tyrosine kinase-IN-4

c-Met/HGFR Cancer

Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor .
HY-P2547

Tyrosine Kinase Peptide 1

Src Others

Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .
HY-149895

Syk-IN-7

Syk Cancer

Syk-IN-7 (compound 17) is an inhibitor of spleen tyrosine kinase (SYK) .
HY-148228

ROS kinases-IN-1

ROS Kinase Cancer

ROS kinases-IN-1 (pag 98) is a ROS tyrosine kinase inhibitor with IC₅₀ value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity .
HY-10331S

Regorafenib-d3

BAY 73-4506-d3

Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

Tunlametinib HL-085	c-Met/HGFR	Cancer
Tunlametinib, an antineoplastic agent, is a **tyrosine kinase** inhibitor .

Labuxtinib	c-Kit	Cancer
Labuxtinib is c-kit tyrosine kinase inhibitor .

Tyrosine kinase-IN-4	c-Met/HGFR	Cancer
Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein **tyrosine kinase** inhibitor .

**Tyrosine Kinase Peptide 1**	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

Syk-IN-7	Syk	Cancer
Syk-IN-7 (compound 17) is an inhibitor of spleen tyrosine kinase (SYK) .

ROS kinases-IN-1	ROS Kinase	Cancer
ROS kinases-IN-1 (pag 98) is a ROS tyrosine kinase inhibitor with IC₅₀ value of 1.22 μM. ROS kinases-IN-1 shows anti-tumor activity .

Regorafenib-d3 BAY 73-4506-d3
Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

HY-101962

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

HY-15656S

Ceritinib-d7 LDK378 d₇	Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Endocrinology Cancer
Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

HY-103032

Multi-kinase inhibitor 1	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent *multi-kinase* inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl .

HY-117718

AG957 TyrphostIN AG957; NSC 654705	Bcr-Abl	Cancer
AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a bcr/abl kinase inhibitor with an IC₅₀ of 2.9 μM for p210 ^bcr/abl autokinase activity .

HY-131669

Dasatinib metabolite M6 DasatINib carboxylic acid	Drug Metabolite	Others
Dasatinib metabolite M6 (Dasatinib carboxylic acid) is an oxidative metabolite of Dasatinib (HY-10181). Dasatinib is a potent and orally active dual Bcr-Abl and Src family tyrosine kinase inhibitor .

HY-148794

Risvodetinib IkT-148009	c-Met/HGFR	Cancer
Risvodetinib is a potent protein tyrosine kinase inhibitor. Risvodetinib involves in synthesis of Abelson protein kinases (c-Abl1, c-Abl2, and c-kit) inhibitor .

HY-P1776

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

HY-N12041

Axl-IN-16	TAM Receptor HIF/HIF Prolyl-Hydroxylase	Cancer
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-125017

Bozitinib 1 Publications Verification PLB-1001; CBT-101; VebreltINib	c-Met/HGFR	Cancer
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .

HY-12768

Sotuletinib Maximum Cited Publications 15 Publications Verification BLZ945	c-Fms	Cancer
Sotuletinib (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .

HY-50895G

Gefitinib ZD1839	EGFR Autophagy Apoptosis	Cancer
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .

HY-12768A

Sotuletinib hydrochloride Maximum Cited Publications 15 Publications Verification BLZ945 hydrochloride	c-Fms	Cancer
Sotuletinib (BLZ945) hydrochloride is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC₅₀ of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs .

HY-N6732

K-252a 10+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-10408

Ki20227 5 Publications Verification	c-Fms VEGFR c-Kit PDGFR	Inflammation/Immunology
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC₅₀s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .

Gefitinib (GMP) ZD1839 (GMP)	Fluorescent Dye
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .

Gefitinib (GMP) ZD1839 (GMP)	Biochemical Assay Reagents
Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor .

**Tyrosine Kinase Peptide 1**	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12041

Axl-IN-16	Structural Classification Natural Products Microorganisms Source classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

Cat. No.	Product Name	Chemical Structure

HY-15656S

Ceritinib-d7

Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

Ceritinib-d7
Ceritinib-d₇ is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tyrosine kinase-IN-1

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products